Angiogenin: A novel inhibitor of neutrophil lactoferrin release during extracorporeal circulation

Schmaldienst S, Oberpichler A, Tschesche H, Horl WH (2003)
KIDNEY & BLOOD PRESSURE RESEARCH 26(2): 107-112.

Download
No fulltext has been uploaded. References only!
Journal Article | Original Article | Published | English

No fulltext has been uploaded

Author
; ; ;
Abstract
Degranulation of polymorphonuclear leukocytes (PMNL) occurs during extracorporeal circulation. A degranulation-inhibiting protein identical to angiogenin was recently isolated from high-flux dialyzer ultrafiltrate. This protein inhibits the release of lactoferrin and metalloproteinases from PMNL in vitro. In the present study, we investigated end-stage renal disease patients undergoing regular hemodialysis treatment with either high-flux dialyzers (n = 51) or low-flux dialyzers (n = 44), and chronically uremic patients undergoing hemodiafiltration (n = 30). Hemodialysis therapy with low-flux polysulfone or cellulose triacetate membranes caused no or only minimal reduction (less than or equal to8%) of plasma angiogenin levels within 2 h of dialysis treatment associated with a 1.6-fold lactoferrin release from PMNL. Hemodialysis therapy with high-flux membranes (e.g. cellulose triacetate, polymethylmethacrylate) or hemodiafiltration resulted in a reduction of plasma angiogenin levels by 20-40% after 2 h associated with a nearly 4-fold PMNL lactoferrin release. The release of PMNL elastase was not affected by the different treatment modalities used. We conclude that high angiogenin plasma levels protect against lactoferrin release from PMNL during extracorporeal circulation in chronically uremic patients. A decrease of plasma angiogenin between 20 and 40% during extracorporeal circulation, however, results in marked PMNL lactoferrin release. This novel mechanism may explain, at least in part, PMNL degranulation also in non complement activating high-flux membranes. Copyright (C) 2003 S. Karger AG, Basel.
Publishing Year
ISSN
eISSN
PUB-ID

Cite this

Schmaldienst S, Oberpichler A, Tschesche H, Horl WH. Angiogenin: A novel inhibitor of neutrophil lactoferrin release during extracorporeal circulation. KIDNEY & BLOOD PRESSURE RESEARCH. 2003;26(2):107-112.
Schmaldienst, S., Oberpichler, A., Tschesche, H., & Horl, W. H. (2003). Angiogenin: A novel inhibitor of neutrophil lactoferrin release during extracorporeal circulation. KIDNEY & BLOOD PRESSURE RESEARCH, 26(2), 107-112. doi:10.1159/000070992
Schmaldienst, S., Oberpichler, A., Tschesche, H., and Horl, W. H. (2003). Angiogenin: A novel inhibitor of neutrophil lactoferrin release during extracorporeal circulation. KIDNEY & BLOOD PRESSURE RESEARCH 26, 107-112.
Schmaldienst, S., et al., 2003. Angiogenin: A novel inhibitor of neutrophil lactoferrin release during extracorporeal circulation. KIDNEY & BLOOD PRESSURE RESEARCH, 26(2), p 107-112.
S. Schmaldienst, et al., “Angiogenin: A novel inhibitor of neutrophil lactoferrin release during extracorporeal circulation”, KIDNEY & BLOOD PRESSURE RESEARCH, vol. 26, 2003, pp. 107-112.
Schmaldienst, S., Oberpichler, A., Tschesche, H., Horl, W.H.: Angiogenin: A novel inhibitor of neutrophil lactoferrin release during extracorporeal circulation. KIDNEY & BLOOD PRESSURE RESEARCH. 26, 107-112 (2003).
Schmaldienst, S, Oberpichler, A, Tschesche, Harald, and Horl, WH. “Angiogenin: A novel inhibitor of neutrophil lactoferrin release during extracorporeal circulation”. KIDNEY & BLOOD PRESSURE RESEARCH 26.2 (2003): 107-112.
This data publication is cited in the following publications:
This publication cites the following data publications:

7 Citations in Europe PMC

Data provided by Europe PubMed Central.

Angiogenin for the Diagnosis and Grading of Dry Eye Syndrome.
Kim WS, Wee SW, Lee SH, Kim JC., Korean J Ophthalmol 30(3), 2016
PMID: 27247515
The Ribonuclease A Superfamily in Humans: Canonical RNases as the Buttress of Innate Immunity.
Koczera P, Martin L, Marx G, Schuerholz T., Int J Mol Sci 17(8), 2016
PMID: 27527162
The mammalian secreted RNases: mechanisms of action in host defence.
Gupta SK, Haigh BJ, Griffin FJ, Wheeler TT., Innate Immun 19(1), 2013
PMID: 22627784
Increased plasma angiogenin level is associated and may contribute to decreased T-cell zeta-chain expression in hemodialysis patients.
Eleftheriadis T, Kartsios C, Pissas G, Liakopoulos V, Antoniadi G, Galaktidou G, Stefanidis I., Ther Apher Dial 17(1), 2013
PMID: 23379493
Plasma vascular endothelial growth factor and angiogenin are positively related to erythropoietin dose in hemodialysis patients.
Eleftheriadis T, Antoniadi G, Liakopoulos V, Pissas G, Galaktidou G, Stefanidis I., Adv Med Sci 58(1), 2013
PMID: 23640951
Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients.
Cheung AK, Greene T, Leypoldt JK, Yan G, Allon M, Delmez J, Levey AS, Levin NW, Rocco MV, Schulman G, Eknoyan G, HEMO Study Group., Clin J Am Soc Nephrol 3(1), 2008
PMID: 18057309
Serum angiogenin in inflammatory bowel disease.
Koutroubakis IE, Xidakis C, Karmiris K, Sfiridaki A, Kandidaki E, Kouroumalis EA., Dig Dis Sci 49(11-12), 2004
PMID: 15628698

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 12771535
PubMed | Europe PMC

Search this title in

Google Scholar